None has been approved in the U.S. yet, but Boehringer Ingelheim is working on interchangeability status for its biosimilar to AbbVie's (NYSE:ABBV) Humira (adalimumab). Interchangeable insulin products should coming in the next few years.
A key requirement of the new guidelines is a "switching study" aimed at demonstrating that alternating between the biosimilar and branded product does not impact safety or efficacy.
Selected tickers: Biogen (NASDAQ:BIIB); Amgen (NASDAQ:AMGN); Vertex Pharmaceuticals (NASDAQ:VRTX); Gilead Sciences (NASDAQ:GILD); Takeda (NYSE:TAK); Bausch Health (NYSE:BHC); Roche (OTCQX:RHHBY); Allergan (NYSE:AGN); AstraZeneca (NYSE:AZN); Bristol-Myers Squibb (NYSE:BMY); GlaxoSmithKline (NYSE:GSK); Johnson & Johnson (NYSE:JNJ); Eli Lilly (NYSE:LLY); Merck (NYSE:MRK); Novo Nordisk (NYSE:NVO); Novartis (NYSE:NVS); Pfizer (NYSE:PFE); Teva Pharmaceutical Industries (NYSE:TEVA)
Subscribe for full text news in your inbox